Short answer
Mineralys Therapeutics, Inc. (MLYS) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$241M
- −457.1% YoY · −512.8% QoQ
- EPS (diluted)
- −$2.88
- −343.1% YoY · −512.8% QoQ
Source: XBRL data from the Mineralys Therapeutics, Inc. (MLYS) Q2 2026 10-Q on SEC EDGAR. USD.
Mineralys Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales before lorundrostat approval
- Net loss $241.1M vs $43.3M YoY; R&D expense $221.4M vs $38.3M
- R&D expenses increased $183.1M, primarily reflecting the $200.0M Tanabe upfront payment
- Cash, equivalents, and investments $661.4M at June 30, 2026; $100.0M Tranche A Loan drawn
- PDUFA target date December 22, 2026; anticipated headwinds include FDA feedback, tariffs, inflation, and geopolitical conflict
Risk Factors
- New debt-servicing risk triggered by June 2026 Loan Agreement, with maturity in 2031 and no expected operating cash flow
- Secured-credit risk from lender security interests covering substantially all assets, including intellectual property
- Covenant-compliance risk from minimum liquidity and future net product revenue requirements beginning 2028
- Default risk includes potential acceleration, collateral foreclosure, and required repayment of principal, interest, and premiums
- Competitive disadvantage from increased leverage versus better-capitalized competitors
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Mineralys Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.